|1.||Gandham, Ravi Kumar: 1 article (11/2015)|
|2.||Tiwari, Ashok K: 1 article (11/2015)|
|3.||Rajmani, R S: 1 article (11/2015)|
|4.||Sahoo, Aditya P: 1 article (11/2015)|
|5.||Chaturvedi, Uttara: 1 article (11/2015)|
|6.||Saxena, Shikha: 1 article (11/2015)|
|7.||Singh, Prafull Kumar: 1 article (11/2015)|
|8.||Kumar, Rajiv: 1 article (11/2015)|
|9.||Gupta, Shishir Kumar: 1 article (11/2015)|
|10.||Shankar, Eswar: 1 article (10/2015)|
|1.||Graft vs Host Disease (Graft-Versus-Host Disease)
01/15/2006 - "NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145."
01/15/2006 - "In this study, we examined whether bortezomib and PS-1145, each of which inhibits NF-kappaB, could protect mice from lethal graft-versus-host disease (GVHD), which is characterized by immune activation and proinflammatory cytokine production. "
01/19/2006 - "Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells."
05/15/2009 - "We quantitatively compared the efficacy of various proteasome inhibitors (MG132, lactacystin and epoxomicin) and IKK inhibitors (BAY 11-7082 and PS1145) to block NFkappaB activity induced by TNFalpha or TPA and to sensitize LNCaP prostate carcinoma cells to apoptosis. "
09/01/2006 - "Finally, therapy with TRAIL plus PS-1145 reversed TRAIL resistance in vivo to produce synergistic growth inhibition in orthotopic Panc-1 tumors. "
11/01/2015 - "The histopathological examination showed that the tumor progression, mitotic, AgNOR, and PCNA indices were significantly reduced in PS1145 treatment groups as compared to PBS control on day 28 of post-treatment. "
11/01/2015 - "We examined the apoptotic effect of PS1145 on DMBA-induced tumor by various histopathological and molecular techniques. "
11/01/2015 - "In the present study, we investigated the effect of IκB kinase-specific blocker PS1145 on DMBA-induced skin tumor of male Wistar rats. "
11/01/2015 - "We conclude that intravenous application of PS1145 promotes direct apoptosis in DMBA-induced skin tumor in male Wistar rats by blocking NF-κB and VEGF activities. "
|4.||Prostatic Neoplasms (Prostate Cancer)
09/30/2014 - "Furthermore, the reduction of prostate cancer cell proliferation by CHIR99021 was potentiated by inhibition of NFκB signaling using the IKK inhibitor PS1145. "
10/13/2015 - "We found that apigenin directly binds with IKKα, attenuates IKKα kinase activity and suppresses NF-ĸB/p65 activation in human prostate cancer PC-3 and 22Rv1 cells much more effectively than IKK inhibitor, PS1145. "
09/15/2006 - "Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity."
09/15/2006 - "Hormone-dependent (LNCaP) and hormone-independent (PC-3 and DU-145) prostate cancer cell lines were exposed to docetaxel alone or combined with the NF-kappaB inhibitor PS-1145 (an inhibitor of IkappaB kinase-2). "
|1.||NF-kappa B (NF-kB)
|3.||Proteasome Endopeptidase Complex (Proteasome)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||3- (4- methylphenylsulfonyl)- 2- propenenitrile